Genocea is developing therapeutics at the forefront of the T cell revolution.
T cells are increasingly recognized as a critical element of the body’s protective immune response to a wide range of pathogens and diseases.
While traditional immunotherapy discovery methods have largely used predictive algorithms to find target antigens, we have been able to successfully leverage ATLAS™, our proprietary, high-throughput technology platform, to identify target antigens of T cells based on actual human immune responses, potentially enabling the rapid development of therapeutic vaccines that stimulate human protective immunity.
We have advanced our lead candidate, GEN-003, a novel T cell-directed immunotherapy for genital herpes, into Phase 2 clinical development, while also exploring earlier-stage candidates in immuno-oncology.
Genocea is headquartered in Cambridge, MA. Our ticker symbol is GNCA.